Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Current Assets (2016 - 2025)

Historic Current Assets for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $21.7 million.

  • Marker Therapeutics' Current Assets rose 9921.3% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 9921.3%. This contributed to the annual value of $22.0 million for FY2024, which is 2858.27% up from last year.
  • Latest data reveals that Marker Therapeutics reported Current Assets of $21.7 million as of Q3 2025, which was up 9921.3% from $14.8 million recorded in Q2 2025.
  • Marker Therapeutics' Current Assets' 5-year high stood at $67.5 million during Q1 2021, with a 5-year trough of $10.9 million in Q3 2024.
  • In the last 5 years, Marker Therapeutics' Current Assets had a median value of $21.7 million in 2025 and averaged $26.6 million.
  • Its Current Assets has fluctuated over the past 5 years, first tumbled by 6481.7% in 2023, then skyrocketed by 9921.3% in 2025.
  • Over the past 5 years, Marker Therapeutics' Current Assets (Quarter) stood at $46.0 million in 2021, then plummeted by 63.86% to $16.6 million in 2022, then grew by 3.06% to $17.1 million in 2023, then grew by 28.58% to $22.0 million in 2024, then fell by 1.31% to $21.7 million in 2025.
  • Its Current Assets was $21.7 million in Q3 2025, compared to $14.8 million in Q2 2025 and $17.0 million in Q1 2025.